Clinical Trial Results: Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment [Phase 2]

View source ↗

Summary

Phase 2 trial results for topical ruxolitinib 1.5% in hidradenitis suppurativa have been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hidradenitis Suppurativa

Drugs mentioned

• ruxolitinib 1.5% topical (ruxolitinib)

Snippet

Sponsor: Milton S. Hershey Medical Center | Conditions: Hidradenitis Suppurativa | Phase 2 | Status: TERMINATED | Results posted: 2026-04-28